Proton-Pump Inhibitors Increase the Risk of Heart Attack by 20%

Heartburn, acid reflux or gastroesophageal reflux disease are often treated with antacids such as Prilosec, Nexium and Prevacid, which are part of a class of drugs known as proton-pump inhibitors, or PPIs. They are among the world's most widely prescribed drugs, generating some $14 billion in annual sales. Researchers at Stanford University have revealed that these popular over-the-counter (OTC) antacids are linked to a 20% higher risk of heart attack.

Researchers analyzed health records of nearly three million people. The study found that about 20 million Americans, or one in every 14 people, use PPIs. Until now, they were considered to be safe unless they were taken with the blood thinner Plavix (clopidogrel). While the study did not prove that antacids cause heart attacks, only that there is an apparent link, scientists believe the problem may involve how the drugs affect the lining of blood vessels.

Common Antacids can Act as Cheaper Anti-cancer Drugs
A recent research has proved that increased survival in colorectal cancer is possible with the use of a popular indigestion medication.

However, another kind of antacid, known as H2 blockers, such as Zantac and Tagamet, showed no higher risk of heart attack.

The study is published in PLOS ONE.

Source-AFP

Research Says Antacids may Lead to 'Difficult to Treat' Small Intestine Ulcers
Antacids that we take to reduce the chances of stomach ulcers we think can be caused by arthritis drugs, may result in irreparable harm to the small intestine, a new McMaster study has revealed

Daily Popping an Antacid to Regulate Stomach Acid Increases Heart Attack Risk
People who take antacids or medication to suppress stomach acid are at greater risk of developing myocardial infarction, commonly known as heart attack.

Better Survival in Head and Neck Cancer in Antacid Users
Better overall survival was seen in patients with head and neck cancer who used antacid medicines to control acid reflux, found a new study from the University of Michigan Comprehensive Cancer Center.